• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus pandemrix? -vaccination

tetano

Editor, Senior Moderator
Immunology. 2015 Feb 1. doi: 10.1111/imm.12448. [Epub ahead of print]
[h=1]H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus pandemrix? -vaccination.[/h] Aditya A[SUP]1[/SUP], Valentini D, Montomoli E, Lapini G, Biuso F, Wenschuh H, Magalhaes I, Maeurer M.
[h=3]Author information[/h]

[h=3]Abstract[/h] A high content peptide microarray containing the entire Influenza A virus (A/California/08/2009(H1N1)) proteome and hemagglutinin proteins from 12 other influenza A subtypes, including the hemagglutinin from the (A/South Carolina/1/1918(H1N1)) strain, was used to gauge serum IgG epitope signatures prior to and after pandemrix vaccination/ or H1N1 infection in a Swedish cohort during the pandemic influenza season 2009. A very narrow pattern of pandemic flu specific IgG epitope recognition was observed in the serum from individuals who later contracted H1N1 infection. Moreover the pandemic influenza infection generated IgG reactivity to two adjacent epitopes of the neuraminidase protein. The differential serum IgG recognition was focused on hemagglutinin 1 (H1) and restricted to classical antigenic sites (Cb) in both the vaccinated controls and individuals with flu infections. We further identified a novel epitope VEPGDKITFEATGNL on the Ca antigenic site (251-265) of the Pandemic flu hemagglutinin, which was exclusively recognized in serum from individuals with previous vaccinations and never in serum from individuals with H1N1 infection (confirmed by RNA PCR analysis from nasal swabs). This epitope was mapped to the receptor-binding domain of the influenza hemagglutinin (HA) and could serve as a correlate of immune protection in the context of pandemic flu. The study shows that unbiased epitope mapping using peptide microarray technology leads to the identification of biologically and clinically relevant target structures, it also shows that H1N1 infection induced a different footprint of IgG epitope recognition patterns as compared to the pandemic H1N1 vaccine. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] Antibodies; Antigens; Epitopes; H1N1 pandemic; Hemagglutinin; Influenza; Neuraminidase; Peptide microarray; Vaccination; Viral

PMID: 25639813 [PubMed - as supplied by publisher]
 
Back
Top Bottom